Patents Examined by Alana Harris Dent
  • Use of facilitates chromatin transcription complex (FACT) in cancer
    Patent number: 10386370
    Abstract: The present invention relates to, inter alia, measuring of at least one component of the facilitates chromatin transcription complex (FACT) for evaluating a tumor, including, for example, determining the aggressiveness of a tumor and directing treatment.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: August 20, 2019
    Assignee: Incuron, Inc.
    Inventor: Katerina Gurova
  • Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
    Patent number: 10377811
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: August 13, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Diagnostic and therapeutic methods and compositions involving PTEN and breast cancer
    Patent number: 10378058
    Abstract: Patients with ErbB2-overexpressing cancers can be given an ErbB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErbB2 targeting agent in an ErbB2-overexpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErbB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: August 13, 2019
    Assignee: Board of Regents of The University of Texas System
    Inventors: Dihua Yu, Xiaoyan Zhou, Yoichi Nagata, Francisco J. Esteva, Aysegul A. Sahin
  • Recombinant polypeptides and methods of use thereof
    Patent number: 10370421
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: August 6, 2019
    Assignee: Imunami Laboratories Pte. Ltd.
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Method for discriminating between prostate cancer and a benign prostate disease
    Patent number: 10371704
    Abstract: A method of analyzing diagnostic information, the method including: measuring a concentration of a mucin-1 (Tn-MUC1), which is reactive with a lectin that recognizes and binds to an N-acetyl-D-galactosamine?serine (threonine) residue, in a blood sample originated from a subject to be diagnosed; comparing the measured value with a threshold value; and estimating that a disease affecting the subject to be diagnosed is not prostate cancer but a benign prostate disease when the measured value of the concentration of Tn-MUC1 is greater than the threshold value.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: August 6, 2019
    Assignee: KONICA MINOLTA, INC.
    Inventors: Katsuko Yamashita, Takatoshi Kaya, Youichi Ide, Tomonori Kaneko
  • Immunotherapy against melanoma and other cancers
    Patent number: 10364281
    Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: July 30, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Annika Sonntag, Toni Weinschenk, Andrea Mahr, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Recombinant polypeptides and methods of use thereof
    Patent number: 10351607
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: July 16, 2019
    Assignee: Imunami Laboratories Pte. Ltd.
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Method for treating cancer with activated T cells
    Patent number: 10335471
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 2, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Recombinant polypeptides and methods of use thereof
    Patent number: 10323071
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: June 18, 2019
    Assignee: Imunami Laboratories Pte. Ltd.
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Recombinant polypeptides and methods of use thereof
    Patent number: 10301364
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: May 28, 2019
    Assignee: Imunami Laboratories Pte. Ltd.
    Inventors: Ya-Huei Chen, Ting-Long Lin
  • Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase
    Patent number: 10301376
    Abstract: Provided are combinations, compositions and kits containing a immune globulin (IG) composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating IG-treatable diseases or conditions. Also provided are methods for subcutaneous administration of immune globulin whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same IG-treatable disease or condition.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: May 28, 2019
    Assignees: Baxalta GmbH, Baxalta Incorporated
    Inventors: Richard Schiff, Heinz Leibl
  • Method for treating cancer with an activated T lymphocyte that selectively recognizes a cancer cell consisting of specific peptide
    Patent number: 10280205
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: May 7, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • CD80 extracellular domain polypeptides and their use in cancer treatment
    Patent number: 10273281
    Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: April 30, 2019
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
  • Conjugate comprising P21 protein for the treatment of cancer
    Patent number: 10259852
    Abstract: The P21 protein is used as a medicament in the treatment of cancer, conjugate comprises a first region comprising the P21 protein, or a homolog functional fragment thereof; and a second region comprising a translocation factor.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: April 16, 2019
    Assignee: Anastasis Biotec Limited
    Inventors: Agamemnon Epenetos, Christina Kousparou
  • Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
    Patent number: 10253076
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: April 9, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
    Patent number: 10239931
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: March 26, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
    Patent number: 10227388
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 12, 2019
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Method and kit for detection of deltanoid-resistant leukemia cells and antibody for use therein
    Patent number: 10197572
    Abstract: The present invention relates to a method and a kit and antibodies utilized therein, allowing to distinguish between leukemia cells resistant to and leukemia cells susceptible to differentiation induced by deltanoids.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: February 5, 2019
    Assignee: WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O.
    Inventors: Ewa Marcinkowska, Aleksandra Marchwicka, Filip Radom, Marta Matusiewicz, Piotr Jakimowicz, Filip Jelen, Maciej Mazurek
  • OX40L fusion protein for the immunotherapy of tumors of veterinary animals
    Patent number: 10196435
    Abstract: Provided is an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment or a biological equivalent thereof and compositions comprising: an isolated recombinant polypeptide comprising an immunoglobulin domain and a canine OX40L extracellular domain polypeptide fragment; and a pharmaceutically acceptable carrier. Also provided are methods for treating or ameliorating the symptoms of cancer in a canine comprising administering an effective amount of the isolated recombinant polypeptide of the disclosure and/or a composition of the disclosure to a canine in need thereof.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: February 5, 2019
    Assignee: University of Southern California
    Inventors: Alan L. Epstein, Peisheng Hu
  • Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
    Patent number: 10184942
    Abstract: The invention pertains to biomarkers for clinical detection of malignancies, especially for early detection of cancers. More specifically, this invention pertains to the role of Natriuretic Peptide Receptor A (NPRA) in cancer (e.g., tumor) progression. Thus, the invention includes materials and methods for the detection and prognosis of malignancies. The invention also pertains to methods for treating malignancies.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: January 22, 2019
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Subhra Mohapatra, Shyam Mohapatra